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Summary
This international multidisciplinary consensus statement was developed to provide balanced guidance on the
safe peri-operative use of opioids in adults. An international panel of healthcare professionals evaluated the
literature relating to postoperative opioid-related harm, including persistent postoperative opioid use; opioid-
induced ventilatory impairment; non-medical opioid use; opioid diversion and dependence; and driving under
the influence of prescription opioids. Recommended strategies to reduce harm include pre-operative
assessment of the risk of persistent postoperative opioid use; use of an assessment of patient function rather
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than unidimensional pain scores alone to guide adequacy of analgesia; avoidance of long-acting (modified-
release and transdermal patches) opioid formulations and combination analgesics; limiting the number of
tablets prescribed at discharge; providing deprescribing advice; avoidance of automatic prescription refills;
safe disposal of unused medicines; reducing the risk of opioid diversion; and better education of healthcare
professionals, patients and carers. This consensus statement provides a framework for better prescribing
practices that could help reduce the risk of postoperative opioid-related harm in adults.
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Recommendations for best clinical
practice
1 All patients undergoing surgery should be assumed
to be at risk of developing persistent postoperative
opioid use and opioid-induced ventilatory
impairment and may need interventions to mitigate
those risks.
2 Consider optimising management of pre-operative
pain and psychological risk-factors before surgery,
including weaning of opioids where possible. Ensure
realistic expectations of postoperative pain control,
both in hospital and after discharge.
3 Provision of opioid analgesia should be guided by
functional outcomes, rather than unidimensional pain
scores alone.
4 Multimodal analgesia should be optimised and patients
educated about the use of non-pharmacological and
non-opioid analgesia to reduce the amount and
duration of opioids required to restore function.
5 Long-acting opioids should not be used routinely for
acute postoperative pain.
6 A patient-centred approach should be used to limit the
number of tablets and the duration of usual discharge
opioid prescriptions, typically to less than aweek.
7 Automated post-discharge repeat prescriptions for
opioids should be avoided. Perform a patient review if
more opioids are requested.
8 Hospitals should have strategies to mitigate the
occurrence of opioid-induced ventilatory impairment.
Specifically, all inpatients receiving postoperative
opioids must have their level of sedation assessed at
appropriate and repeated intervals.
9 Modifiable factors that have been identified as
increasing the risk of opioid-induced ventilatory
impairment and persistent postoperative opioid use
should be addressed. These factors include medicines
with sedative properties; long-acting opioids; and
reliance on unidimensional pain scores alone to guide
prescribing and titration.
10 Patients should be advised on safe storage and
disposal of unused opioids and directed to avoid
opioid diversion to other individuals (e.g. sharing with
friends and family).
Whywas this consensus statement
developed?
Opioids are effective anti-nociceptive medicines that form
an integral component of balanced multimodal analgesic
strategies for the management of acute pain in
postoperative patients [1, 2]. However, over the past decade
it has been increasingly appreciated that, in efforts to
improve pain relief after surgery, peri-operative prescribers
have unwittingly contributed to persistent postoperative
opioid use in some patients [3]. The economic and social
repercussions of the opioid crisis are well documented in
the USA [4], but it is now a phenomenon across many
countries [5]. One study has shown that although 91% of
patients in the USA were prescribed opioids
postoperatively, only 5% of patients in seven other countries
received such prescriptions [6]. However, comprehensive
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global data are not available and it is conceivable that
postoperative opioid usage in other countries may increase
if left unchecked [7]. In addition to the social and economic
costs of opioid misuse, there are personal costs, with many
people dying from opioid overdose [8, 9]. These opioid-
related deaths are predominantly a result of opioid-induced
ventilatory impairment [4].
Over the past two decades, guidelines for the
management of postoperative pain initially promoted the
unrestricted titration of opioids to unidimensional pain
scores, often as part of the now-discredited ‘Pain as the 5th
Vital Sign’ campaign [10–13]. With rising concern that peri-
operative opioid use may accidentally contribute to harm
from persistent postoperative opioid use; opioid-induced
ventilatory impairment; opioid misuse and diversion; and
driving under the influence of prescription opioids, there is
increasing enthusiasm for opioid-free anaesthesia and
analgesia [1, 14, 15]. Currently, opioid-free techniques are
poorly defined, with limited evidence to support the
adjuvants recommended [16]; thus opioids will continue to
be an important element of pain management in many
postoperative patients. It is, therefore, necessary to focus on
opioid stewardship and the multiple components of the
healthcare systemneeded to deliver thesemedicines safely,
rather than relying solely on opioid-free techniques [4].
This international multidisciplinary consensus
statement was developed to provide balanced guidance on
the safe peri-operative use of opioids, facilitating optimal
functional recovery and reducing the risk of opioid-related
harm in adult surgical patients. While intra-operative
strategies are important, they are complex and
heterogeneous, and beyond the scope of this document.
Howdoes this consensus guideline
differ fromother available statements?
This consensus statement discusses the judicious and safe
use of peri-operative opioids from the moment of
contemplation of surgery until full recovery with analgesic
medicines weaned safely and deprescribed. In addition, it
proposes strategies that should be implemented by
individual clinicians as well as multidisciplinary teams to
promote recovery through the use of multimodal opioid-
inclusive analgesia, while simultaneously discussing those
aiming to reduce the risk of harm from persistent
postoperative opioid use. The topics of non-medical opioid
use and opioid diversion and dependence, including in
friends and family [17], are also covered. Furthermore,
unlike other guidelines, strategies required to reduce the
other significant, albeit less commonly discussed, harm
associated with peri-operative opioid use, namely opioid-
induced ventilatory impairment – both in hospital and after
discharge [18] – are included, as well as the need to
consider the risks associated with driving under the
influence of prescription opioids [19, 20].
This guidance should assist healthcare professionals
and hospitals across the world to implement effective
opioid stewardship practices that achieve a balance
between the administration of sufficient opioid analgesia to
facilitate recovery and restoration of function, while
concurrentlyminimising the risk of opioid-related harms.
Methods
This is an international multi-disciplinary consensus
statement. Authors were selected based on clinical or
academic expertise, and included anaesthetists, pain
specialists, surgeons, a primary care physician, nurse and
pharmacist from Australia, India, Italy, the Netherlands,
the UK and the USA. Attempts to include authors from
several other countries, regions and subspecialties were
unsuccessful, but the authorship provides a broad reach
of peri-operative clinicians over four continents. Evidence
to formulate recommendations was identified by
performing a directed literature review of data relevant to
persistent postoperative opioid use; opioid-induced
ventilatory impairment; non-medical opioid use; diversion
and dependence; and driving under the influence of
prescription opioids. Observational and interventional
studies, as well as systematic reviews related to the topics
of interest, were sought. Although a formal systematic
review was not conducted, analysis and interpretation of
the relevant studies was performed. Recommendations
were made based on best evidence or, in the absence of
such, on expert opinion, although no grading of the
evidence was made. All recommendations were then
included in a three-round Delphi process [21]. The first
round involved the development of a long list by the
authors. In the second round, all authors voted to include
or remove each recommendation. Comments regarding
content and clarity were also made. Recommendations
that had ≥ 50% consensus for inclusion proceeded to the
third round and were revised to address the comments.
Following the third round, those recommendations with
≥ 75% consensus were chosen. Finally, these 10
recommendations for best clinical practice were ratified
and included in the guidelines.
Persistent postoperative opioid use
The search for a reliable definition of persistent
postoperative opioid use has provided enough
inconsistency to fuel two recent systematic reviews [22,
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23]. For the purposes of this document, persistent
postoperative opioid use is defined as patients taking any
opioids prescribed for postoperative pain for longer than
90 days after surgery. This aligns with the International
Classification of Diseases 11th Revision (ICD-11) definition
of chronic postsurgical pain as pain that persists beyond
3 months after surgery, that is, past normal healing time
[24]. Studies, mainly undertaken in North America, have
demonstrated that 0.1–26% of opioid-na€ıve patients, and
35–77% of patients with previous opioid exposure
continue to take opioids for more than 3 months
postoperatively when healing is complete and acute pain
would have ceased [23].
There are many political, economic, commercial and
societal drivers associatedwith prescribed opioidmisuse [7,
25] (Fig. 1). An in-depth discussion of these factors is
beyond the scope of this article.
Reducing the risk: recommendations
and rationale
As well as the presence of socio-economic factors
influencing persistent postoperative opioid use, other
Figure 1 Risk-factors for prescribed opioidmisuse.
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factors are modifiable and can be attenuated to reduce
harm (Fig. 2).
Pre-operative factors
Even before the patient has surgery, some factors can be
identified to enable interventions to mitigate harm from
persistent postoperative opioid use.
Pre-operative opioid use
The strongest predictor of persistent postoperative opioid
use is pre-existing chronic opioid use. The incidence of
persistent postoperative opioid use can be up to 10 times
higher in those taking opioids long-term before surgery
than in opioid-na€ıve patients [23]. There appears to be a
dose-dependent effect whereby higher doses increase the
risk of persistent postoperative opioid use. In a study of
patients undergoing hip or knee arthroplasty, an oral
morphine equivalent dose of 60 mg.day1 or higher was
associated with an 80% probability of persistent
postoperative opioid use [26]. The reduction of opioids
before surgery is likely to confer benefit both in the
immediate and longer-term postoperative period [27], but
rapid or forced tapers should be avoided [28, 29]. A pre-
operative multidisciplinary team approach providing plans
to taper opioid doses and improve patient pain, function
and psychological distress is possible and leads to
decreases in pre-operative and postoperative pain,
improvements in pre- and postoperative depression and
anxiety, and better patient function [30, 31]. Referral to
chronic pain management and/or addiction medicine
servicesmay be beneficial for somepatients.
Pain andpsychological disorders
The presence of pre-operative chronic pain is a significant
risk-factor for persistent postoperative opioid use, as are
affective disorders including anxiety, depression and
catastrophic thinking [32]. Possibly as proxy measures, the
pre-operative use of antidepressants or benzodiazepines
has also been linked to higher rates of persistent
postoperative opioid use [23, 32, 33]. Substance use
disorders, including tobacco, alcohol and cocaine abuse,
also increase the likelihood of persistent postoperative
opioid use [32, 33].
In the early postoperative period, pre-operative
anxiety, depression, catastrophising and emotional
distress levels have also all been shown to correlate with
higher pain intensity and opioid requirements [34, 35]. It
is, therefore, recommended that pre-operative pain and
psychological risk-factors should be optimised before
surgery.
Figure 2 Modifiable risk-factors and suggested recommendations or rationale for persistent postoperative opioid use (PPOU).
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Patient expectations
Pre-operative patient education providing realistic
expectations regarding pain after surgery, together with
information around multimodal analgesia (incorporating
non-pharmacological techniques as well as non-opioid
analgesia) [36] and education about the risks and side-
effects of opioids, can reduce postoperative opioid use and
decrease the duration of opioids taken after discharge [37].
It is recommended that appropriate pre-operative
education addressing expectations of pain management
should be provided to all patients where, in order to restore
function, somepain is to be expected.
Inadequate patient assessment
The predominance of patient factors (opioid use,
chronic pain and psychological co-morbidities) as
predictors of persistent postoperative opioid use allows
early identification of vulnerable individuals. Scoring
systems have been used for patients with chronic pain
to predict who may be at risk of opioid use disorder
[38]. Similar tools may prove useful in the pre-
assessment setting to identify patients at risk, allowing
targeted mitigation of modifiable factors, such as
interventions to address negative psychology or coping
strategies or weaning of pre-operative opioids. There is
evidence that some scoring systems have good
sensitivity and specificity for persistent postoperative
opioid use [39, 40]. Other tools also exist, but their
utility in the peri-operative setting is uncertain [41]. A
review described the evidence for psychological
interventions improving postoperative recovery or
reducing persistent postoperative opioid use as weak
[42], but this remains a novel area delivering promising
results [30, 31].
Patients at increased risk of persistent postoperative
opioid use should be identified at pre-operative
assessment.
Assumption of low-risk procedures
It has been suggested that certain types of surgical
procedures are associated with a high risk of persistent
postoperative opioid use [43] (and thus, by extension, some
operations that may be low risk), but this has not been
consistent across studies [23]. Patients undergoing minor
surgery seem to be just as vulnerable to persistent
postoperative opioid use as those undergoing major
procedures [32, 33]. Consequently, all patients undergoing
surgery should be assumed to be at risk of developing
persistent postoperative opioid use and will need
interventions tomitigate that risk.
Postoperative factors
In addition to modifying pre-operative factors, it is
necessary to amend postoperative care to reduce the risk of
persistent postoperative opioid use.
Over-reliance on unidimensional pain scoring
The use of unidimensional pain scores, such as the
numerical pain scale, may provide unrealistic expectations
to patients (i.e. that the goal is to reduce a pain score to zero)
and has been found to drive postoperative opioid
prescribing as clinicians aspire to chase that goal [12].
Functional outcomes are now preferred to complement
pain scoring and guide pharmacological pain management
[12, 44]. It is, therefore, recommended that provision of
immediate-release opioid analgesia for both inpatients and
after discharge should be guided by functional outcomes,
rather than unidimensional pain scores alone [12, 45]. An
example of a functional outcome tool that is gaining
acceptance is the Functional Activity Scale [12, 46–48], as
shown in Box 1.
In addition, relevant functional activity may be both
procedure- and time-specific. Moreover, it must be
remembered that some pain is not opioid-responsive but
may lead to increasing yet ineffective opioid doses, with the
associated risk of opioid-induced ventilatory impairment
and, later, persistent postoperative opioid use. Patients
whose pain is not following an expected trajectory should
be identified early as this may signify postoperative
complications, neuropathic pain or psychological distress.
Over-reliance on opioid analgesia
Multimodal analgesia reduces opioid use in the
immediate postoperative period [49], so it is likely that it
will continue to be opioid-sparing once patients are
discharged from the hospital. The goal remains to
provide postoperative pain relief with rapid restoration of
Box1: Functional Activity Scale
A No limitation: the patient is able to undertake the
activity without limitation due to pain;
B Mild limitation: the patient is able to undertake the
activity, but experiencesmoderate to severe pain;
C Significant limitation: the patient is unable to
complete the activity due to pain or pain treatment-
related adverse effects.
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function, rather than eliminate opioids and risk
compromising patient care [3]. Even before discharge,
opioid weaning strategies should be in place so that, as
a patient recovers, progressively lower doses of opioids
are administered before being stopped [50, 51].
Long-acting opioids and compound analgesic
formulations
Long-acting opioids (also known as sustained-, modified-
or extended-release formulations, as well as transdermal
opioid patches) are one of the three major modifiable
risk-factors for persistent postoperative opioid use [52–
54]; repeat prescriptions and excess tablets on
discharge being the other two [54]. In addition, they
show no benefit in postoperative pain management [55]
and increase the risk of opioid-induced ventilatory
impairment, so should not be used for the treatment of
postoperative pain in hospital or on discharge [56, 57].
Combination analgesics, such as tablets containing
paracetamol (acetaminophen) combined with opioids,
are not advised for postoperative pain as the fixed
doses do not allow titration to patient need, nor the
flexibility required for weaning [58].
Consequently, opioids should only be given as
immediate-release formulations for postoperative pain
management, both in hospital and on discharge. This
recommendation aligns with those promulgated by a
number of regulatory, advisory and professional bodies [29,
57, 59–62].
Dischargeprescribing factors
The time just before discharge provides further
opportunities to mitigate the risk of harm from persistent
postoperative opioid use.
Over-reliance on opioids after hospital discharge
Discharge opioid prescribing plays a crucial role in
persistent postoperative opioid use and opioid diversion.
Multimodal analgesia remains important after discharge to
reduce the reliance on opioids. However, many patients
receive a discharge prescription for opioids only [63],
risking an undue emphasis on their importance and
superiority over other analgesics. It should also be
emphasised to patients that immediate-release opioids
should only be used to promote functional recovery rather
than eliminate pain [45]. There is no place for long-acting
opioids on discharge.
It is, therefore, necessary that patients are educated
about the use of non-pharmacological and non-opioid
analgesia to reduce the amount and duration of opioids
required to restore function.
Overprescribing of opioids on hospital discharge
The number of opioid tablets prescribed at discharge often
far exceeds the number used, with between 40% and 94%
left untaken [64, 65]. This reservoir of unused opioids
presents significant risks to the community. In the UK, oral
morphine solution is commonly used for in-hospital
analgesia: at low concentrations (10 mg in 5 ml), it is a
schedule 5 controlled drug, requiring only one nurse to
check and give it, allowing swift administration for rapid
analgesia [66]. However, opioid solutions should not be
used for discharge prescribing as the size of the bottles
precludes safe monitoring or dose control, with a high
likelihood of leftover medicine, and often unappreciated
risk to the patient [67].
When dispensing discharge opioids, four factors
need to be considered. The first is that the quantity of
opioids dispensed at discharge directly impacts patient-
reported opioid consumption after surgery [68], with
patients given more tablets at discharge likely to take
more opioids than those given a small number. This also
increases the risk of persistent postoperative opioid use
[69]. The second factor is the type of surgery [45, 70],
modified by the third factor, a patient-centred approach,
which takes into account the patient’s opioid requirements
the day before discharge [71, 72], and which should be
used to limit both the duration and the number of opioid
tablets in discharge opioid prescriptions. Finally, the
duration of discharge opioid prescription should usually
be limited to 3–5 days [73], but extended to 7 days in
some circumstances [45]. As the patient recovers, their
opioid requirements will decrease. The opioid dose must
be weaned accordingly, so patients and carers must be
educated on how to reduce and deprescribe their opioids
(Fig. 3). Crucially, patients should be advised on how to
store and dispose unused opioids safely and not to share
opioids with friends or family.
Inexperienced prescribers
Commonly, it is the most junior hospital doctors who are
tasked with prescribing discharge analgesia [55]. Stepwise
interventions have been shown to be of benefit in improving
the safety and appropriateness of their opioid prescribing,
including targeted education; lowered prescription
defaults on automated prescribing systems; and clinician
dashboards to allow peer-to-peer comparison in adherence
to protocols [55]. Junior hospital staff need support and
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teaching for appropriate and safe discharge opioid
prescribing.
Post-discharge factors
Once the patient has been discharged, there are necessary
interventions to reduce the risk of persistent postoperative
opioid use.
Repeat opioid prescriptions
As repeat and refill prescriptions of opioids are one of the
major modifiable risk-factors for persistent postoperative
opioid use [54], repeat prescriptions for opioids should be
avoided. Each additional refill has been found to increase
the risk of opioid misuse (encompassing diagnoses of
opioid dependence; abuse; or overdose) by 40%, with each
additional week of opioids taken raising the risk of misuse
by 20% [69].
It must be communicated to primary care teams that a
request for more opioids should initiate a patient review
rather than an automated repeat prescription. If the patient
is still requiring postoperative opioids beyond the normal
healing period for that surgery, or they are taking opioids
90 days after surgery, they should be referred to pain
specialists for opioid weaning or assessment for chronic
postsurgical pain.
Lack of safe storage anddisposal
Up to 90% of patients fail to dispose excess opioids after
surgery [74] and approximately 75% of patients report that
their prescription opioids are not stored in locked
containers [64], increasing the risk of accidental poisoning
and drug diversion. Paediatric mortality from unintentional
opioid overdose has increased three-fold in the last
20 years and has followed a similar temporal course to adult
overdose deaths [75].
Patients and carers must be educated on the need to
store opioids securely and dispose excess medicines safely
to reduce the likelihood of patients keeping leftover opioids
[76] and to reduce community harm.
Opioid-induced ventilatory impairment
Opioid-induced ventilatory impairment can be defined as
type-2 respiratory failure associated with opioid
administration and high arterial partial pressures of carbon
dioxide with or without hypoxaemia. It is caused by one or
more of the following three factors:
Figure 3 Reverse pain ladder to promote postoperative analgesic deprescribing. NSAID, non-steroidal anti-inflammatory
drugs.
8 © 2020 Association of Anaesthetists
Anaesthesia 2020 Levy et al. | Prevention of postoperative opioid-related harm
1 Depression of the respiratory centre in the brainstem,
leading to a reduction in alveolar ventilation (reduced
respiratory rate and/or tidal volume).
2 Reduced oropharyngeal muscle tone, which can result
in upper airway obstruction [77].
3 Depression of the hypothalamus leading to increased
arousal thresholds and reduced wakefulness
(sedation) [77].
These processes, alone or in combination, can lead to
severe opioid-induced ventilatory impairment which, if
unrecognised and untreated, may result in brain injury or
death [78]. As depression of the respiratory centre is only
one component of this triad, opioid-induced ventilatory
impairment is amore appropriate term than opioid-induced
respiratory depression [18].
As routine measurement of arterial partial pressures
of carbon dioxide is not possible, investigators usually
define opioid-induced ventilatory impairment using
surrogate measures that include respiratory rate (often
arbitrarily defined as < 8 or 10 breaths.min1); peripheral
oxygen saturation; level of sedation; and rates of naloxone
administration. Unfortunately, good evidence showing a
reliable correlation between these measures and arterial
partial pressures of carbon dioxide is lacking [18].
Thus, the reported incidence of postoperative opioid-
induced ventilatory impairment is difficult to determine.
Reported rates range from 0.04% to 41%, depending on the
measure used [79].
Detection of opioid-induced
ventilatory impairment
Harm from opioid-induced ventilatory impairment is
preventable in the majority of cases if detected and
managed at an early stage [80]. Routine use of continuous
pulse oximetry has been recommended [51]. However,
hypoxaemia may be a very late sign of hypoventilation [77,
81], especially if the patient is receiving supplemental
oxygen [77, 81–83]. In addition, reduced oxygen saturations
may result from causes other than opioid-induced
ventilatory impairment.
Continuous monitoring of carbon dioxide partial
pressures, for example, using capnography, as a
measure of ventilation has also been recommended in
selected patients [51], but is commonly limited to
higher-acuity settings. However, carbon dioxide partial
pressures obtained using capnography may not always
correlate well with arterial partial pressures of carbon
dioxide [81].
The lack of reliability of respiratory rate as a
measure of opioid-induced ventilatory impairment is also
well recognised. In 1988, a small case series
demonstrated that neither respiratory rate nor oxygen
saturation correlated with arterial partial pressures of
carbon dioxide, while sedation levels did [82].
Subsequently, the authors developed a five-point
sedation scale to add to routine monitoring practices
[84]. Since that time other variations of this sedation
scoring system have been published [18].
The significance of sedation as a better clinical
indicator of opioid-induced ventilatory impairment than
respiratory rate was highlighted in a study in which
immediate-release opioids were given ‘as needed’ to
reduce pain scores to four or less after the introduction of
the ‘Pain as the 5th Vital Sign’ policy [85]. As well as
demonstrating that titration of opioids to unidimensional
pain scores doubled the risk of opioid-induced ventilatory
impairment, this study showed that reduced levels of
consciousness were a more reliable marker of opioid-
induced ventilatory impairment than reduced respiratory
rates [85]. A closed-claims analysis of patients who
developed severe postoperative opioid-induced ventilatory
impairment further confirmed the importance of monitoring
sedation levels [80].
Fixed risk-factors for opioid-induced
ventilatory impairment
Reported risk-factors for opioid-induced ventilatory
impairment include older age; sleep-disordered
breathing; obesity; renal impairment; respiratory, cardiac
and neurological diseases; diabetes mellitus; tolerance
to opioids; and genetic variations in opioid metabolism
[51, 81, 83, 86]. The higher risk in opioid-tolerant
patients likely relates to differential tolerance to opioids
[87–89].
However, many patients who develop opioid-
induced ventilatory impairment have no identifiable risk-
factors [51, 78, 80]. Therefore, all patients given opioids
postoperatively must be considered to be at risk [51,
83, 86, 90].
Reducing the risk: recommendations
and rationale
Modifiable risk-factors for opioid-induced ventilatory
impairment that have been identified are summarised in
Fig. 4 [51, 79, 80, 83, 86, 91–94]. Recommendations are
based on the avoidance of these risk-factors.
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Age-adjusted opioid dosing
It is known that age is a better predictor of opioid
requirements than patient weight, with requirements
decreasing as age increases [18, 95]. This appears to be
primarily a result of increased brain sensitivity to opioids
rather than age-related changes in pharmacokinetics, which
are usually not of the magnitude needed to account for the
up to four-fold difference between younger and older
patient groups [96]. Initial opioid doses should, therefore,
be based on patient age and not weight, as older patients
require lower doses to achieve analgesia and also to
develop opioid-induced ventilatory impairment [18].
Titrationof opioid dose topatient function
As noted above, reliance on unidimensional pain scores
alone to guide titration of opioids increases the risk of
opioid-induced ventilatory impairment [85]. Measures of
effectiveness of analgesia should not rely on these scores
alone. The focus should change to an assessment of patient
function [18, 44, 97].
Avoidance of long-acting opioid formulations and
sedatives
The slow onset times of modified-release oral and
transdermal opioids make safe and rapid titration of opioids
(both upwards and downwards) impossible. The use of these
formulations increases the risk of opioid-induced ventilatory
impairment [90] and they are not recommended for the
management of postoperative pain [57, 86, 91, 98].
Concurrent use of opioids and other sedating medicines
(including benzodiazepines and gabapentinoids) increases
the risk of opioid-induced ventilatory impairment [18, 51, 79,
80, 92, 99]. Thus, regulatory agencies recommend caution
when combinations of gabapentinoids and opioids are used
[93, 94].
Opioid-sparing or opioid-free techniques
Opioid-sparing or opioid-free techniques are sometimes
recommended to minimise or avoid the need for
postoperative opioids. Currently, there is no good evidence
to show that such regimens reduce the risk of opioid-
induced ventilatory impairment.
Non-opioid-responsive pain
A less recognised risk is the use of opioids in patients
with non-opioid-responsive pain [90]. If the patient’s pain
does not seem to be responding to escalating doses of
opioids, and especially if the patient is becoming
sedated, non-opioid-responsive pain must be considered
and alternative analgesic options employed. Continued
Figure 4 Modifiable risk-factors and suggested recommendations or rationale for opioid-induced ventilatory impairment (OIVI).
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use of opioids can lead to opioid-induced ventilatory
impairment.
Useof sedation scores
As sedation is currently the most reliable clinical marker
of opioid-induced ventilatory impairment, all patients
given an opioid for management of their acute pain must
have their level of sedation assessed at appropriate and
repeated intervals to allow detection and treatment of
opioid-induced ventilatory impairment [18, 51, 83].
Examples of sedation scores are summarised in Table 1
[84, 90, 100]. It is recommended that a sedation scoring
system containing ‘S’ is not used as the patient may not
be woken properly to have their level of sedation
assessed more accurately. They may wake easily, but
then either stay awake or have difficulty staying awake
[18, 90]. If the latter is the case, the opportunity to
recognise and treat opioid-induced ventilatory
impairment before significant patient harm has occurred
may be lost.
Standardorders
Standard orders, often used with techniques such as
patient-controlled, epidural or regional analgesia, aim to
maximise analgesia as well as patient safety. Hospitals
should have standardised order sets automatically linking
all opioid prescribing and monitoring. At a minimum, these
must include instructions outlining appropriate actions to
be taken if over-sedation occurs [18, 83, 90].
Institutional factors
Education is a necessary component of good opioid
stewardship but may not by itself reduce the risk of
postoperative opioid-induced ventilatory impairment [101].
However, implementation of a ‘solutions bundle’ which
includes the introduction of all of the aforementioned
recommendations has been demonstrated to be effective in
reducing the incidence of opioid-induced ventilatory
impairment [86].
Post-discharge factors
Information on the risk of opioid-induced ventilatory
impairment after surgical discharge is limited. While
uncommon, it is more likely to occur within the first 30 days
after discharge andwith higher opioid doses [102, 103]. It is,
therefore, sensible to apply many of the strategies
summarised in Fig. 2.
Patients and carers must know about the risks, signs
and management of opioid-induced ventilatory
impairment; that they must avoid concurrent use of
medicines with sedative effects and alcohol while taking
opioids; andwhen to call for emergency assistance.
Non-medical use of opioids andopioid
diversion
Non-medical opioid use is use without a prescription or use
for reasons other than that for which the opioid was
prescribed. Opioid diversion is the transfer by any means of
a legitimately prescribed opioid(s) to a party other than the
individual for whom it was originally prescribed [17].
Diversion is an important source of opioids, with
addiction surveys finding that around 50% of adults who
misuse opioids obtain them from friends and family [104,
105]. Furthermore, 55% of adolescents and young adults
who have developed opioid addiction obtained their
opioids through similar sources [106].
Table 1 Comparison of three commonly used sedation scores.
Sedation scores [84]
Paseroopioid-induced
sedation scale [100]
Sedation score recommendedby
ANZCA [90]
0 (none) – alert
1 (mild) –occasionally drowsy, easy to arouse
2 (moderate) – frequently drowsy, easy to arouse
3 (severe) – somnolent, difficult to arouse
S (sleeping) – normal sleep, easy to arouse
S – Sleep, easily aroused
1 –Awake and alert
2 –Occasionally drowsy
3 – Frequently drowsy, arousable,
drifts off to sleepduring conversation
4 – Somnolent, minimal or no response
to stimulation
This scalewas subsequently updated,
and each score is now accompanied by
instructions outlining the appropriate
actions to be taken [51, 86]
0 –Wide awake
1 – Easy to rouse (and can stay awake)
2 – Easy to rousebut unable to
remain awake
3 –Difficult to rouse
A score of 2 is taken to indicate early
OIVI and, therefore, the aim shouldbe
to titrate an opioid so that a patient’s
sedation score is always less than 2
Reproduced fromBowen et al. [18], with permission.
OIVI, opioid-induced ventilatory impairment; ANZCA, Australian and New Zealand College of Anaesthetists and Faculty of Pain
Medicine.
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The causes of opioid diversion are multifactorial but
include overprescribing of discharge opioids and creating a
pool of opioids in the community that can then be diverted
[107, 108]; unsecured storage of opioids; and inadequate
safe disposal of unused opioids [74].
As unused opioids are a reservoir for opioid diversion,
prescribers should limit the amount of discharge opioids
prescribed [109]. Patients should be informed to safely
dispose unused opioids and not to share opioids with friends
or family. Education on the need to storeopioids securely and
dispose excess medicines safely decreases the likelihood of
patients keeping leftover opioids [76, 110] and reduces the
amount of opioids available for community harm.
Driving under the influence of
prescription opioids
Prescribed opioids impair driving skills and cognitive
reasoning in a similar manner to alcohol. Driving under the
influence of drugs, including prescribed opioids, is now
recognised to be amajor cause ofmotor vehicle collisions and
subsequent fatalities [19, 20, 111], particularly if the person
commenced the opioidwithin the previous 30 days [112].
In response to the increasing public health and traffic
safety concerns of drug-driving, many countries have now
introduced legislation to either make drug-driving illegal or
to prosecute drivers whose driving is impaired and are
found to have blood drug levels of certain prescribed
medicines, including opioids, that exceed predefined
thresholds [113].
Consequently, patients should be advised of the
dangers and the legal implications of driving while taking
opioids prescribed for postoperative pain and that they
should not drive until they have stopped the opioids.
Opioid stewardship
Opioid stewardship has been described as co-ordinated
interventions designed to improve, monitor, and evaluate
the use of opioids in order to support and protect human
health [114]. Opioids remain a core component of peri-
operative multimodal analgesia to promote optimal
functional recovery in many surgical patients. Effective
opioid stewardship is important to minimise the risk of
opioid-related harm.
Implementing opioid stewardship
It has been suggested that opioid stewardship is composed
of six components: recognising the risk of opioid-related
harms; educating patients (and healthcare providers);
creating realistic patient expectations; the use of
multimodal analgesia; controlled prescribing; and early
referral to pain specialists [115]. However, for safe and
effective opioid stewardship a full package of interventions
needs implementation and, while individual practitioners
play a role, a transformation of services needs to happen at
local and national levels (Table 2). While these include
increasing the knowledge of healthcare professionals,
patients and their carers, education should only be one
component of an institution’s strategy to improve opioid-
related safety [116]. Education alone has been found to be
one of the least effective interventions in the hierarchy of
medicine safety risk-reduction strategies. It, therefore,
needs to be supplemented by more effective but harder to
implement system-focused strategies such as the use of
forcing functions; barriers and fail-safes; automation;
standardisation; and protocols, together with warnings;
alerts; checklists; and reminders [116].
Research andquality improvement
Currently, most of the research in opioid stewardship and
opioid-related adverse drug events originates from the
USA. However, use and misuse of prescribed opioids is not
restricted to the USA. Therefore, more country-specific
research is needed to address national and cultural issues
around persistent postoperative opioid use and opioid-
induced ventilatory impairment, with further research to
define the optimal strategies required to implement safe
opioid stewardship practices.
Limitations
Many of the recommendations in this guideline are
supported by a limited evidence base and are dependent
on expert opinion. The limited evidence and heterogeneity
of the nature of the questions asked precluded a systematic
review and objective grading of recommendations. A
further limitation of this guideline was the inability to include
authors from more countries and additional subspecialties.
The scope of this guideline did not extend to short-term
side-effects of opioids such as constipation, confusion,
itching, nausea and vomiting. Nevertheless, this guideline
should inform future research and help strengthen the
evidence base.
Conclusion
While the peri-operative use of opioids has the capacity to
promote recovery after life-saving or life-enhancing surgery,
their use can be associated with harm from persistent
postoperative opioid use; opioid-induced ventilatory
impairment; opioid diversion; and driving under the influence
of prescription opioids. Institutional opioid stewardship is
required to minimise the risk of opioid-related harm. This will
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require the multidisciplinary involvement of anaesthetists;
surgeons; pain specialists; pharmacists; nursing staff;
physiotherapists; primary care clinicians; hospital
management; and patients to adopt the recommendations
from this consensus statement to local practice.
In addition to local changes, there is the requirement
to ensure that all healthcare professionals are aware of the
risks and benefits of peri-operative opioid use and can
apply and discuss these with their patients. Therefore, the
principles of safe opioid stewardship should be embedded
in the undergraduate, postgraduate and in-hospital
curricula of all healthcare professionals. Furthermore, all
opioid-related serious adverse events should be audited
and investigated to facilitate learning and reflection to
prevent re-occurrence. With the implementation of these
strategies the accidental risk of iatrogenic harm from the
use of peri-operative opioid use in adults could be
minimised.
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